Scarica l'app Stockscreener
5.67
0.00%
0.00
Dopo l'orario di chiusura:
5.61
-0.06
-1.06%
Precedente Chiudi:
$5.67
Aprire:
$5.77
Volume 24 ore:
278.29K
Relative Volume:
1.20
Capitalizzazione di mercato:
$136.49M
Reddito:
$34.26M
Utile/perdita netta:
$-46.61M
Rapporto P/E:
-1.1043
EPS:
-5.1345
Flusso di cassa netto:
$-76.16M
1 W Prestazione:
+22.99%
1M Prestazione:
+45.76%
6M Prestazione:
+22.99%
1 anno Prestazione:
+12.28%
Intervallo 1D:
$5.40
$6.05
Intervallo di 1 settimana:
$4.48
$6.05
Portata 52W:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Nome
Precision Biosciences Inc
Settore
Industria
Telefono
919-314-5512
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
5.67 | 136.49M | 34.26M | -46.61M | -76.16M | -5.1345 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Iniziato | Guggenheim | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-06-09 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Ripresa | BTIG Research | Buy |
| 2020-04-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-05 | Iniziato | Stifel | Buy |
| 2020-02-25 | Iniziato | William Blair | Outperform |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-22 | Iniziato | Barclays | Overweight |
| 2019-04-22 | Iniziato | Goldman | Buy |
| 2019-04-22 | Iniziato | JP Morgan | Overweight |
| 2019-04-22 | Iniziato | Jefferies | Buy |
Mostra tutto
Precision Biosciences Inc Borsa (DTIL) Ultime notizie
Precision BioSciences Stock (ISIN: US74019P1084) Surges on Q4 Profit Turnaround Amid Analyst Upgrade - AD HOC NEWS
Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative - simplywall.st
Jefferies cuts Precision BioSciences stock price target on valuation - Investing.com
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Precision BioSciences Advances PBGENE-DMD Trial, Putting New Focus on Duchenne Gene Therapy - TipRanks
Precision BioSciences (DTIL) Swings to $1.05 EPS in Q4, Reversing $2.22 Year-Ago Loss - AlphaStreet
Precision BioSciences (DTIL) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Bus - pharmiweb.com
Precision BioSciences presents preclinical data on DMD therapy By Investing.com - Investing.com Nigeria
Precision BioSciences (DTIL) Surpasses Q4 Revenue Expectations - GuruFocus
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea - GuruFocus
Precision BioSciences Q4 2025 Earnings: $20.1M Profit on $34.2M RevenueNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Precision Biosciences 2025 10-K: Revenue $34.3M, GAAP net loss $(45.7M) - TradingView
Precision BioSciences: Q4 Earnings Snapshot - Bluefield Daily Telegraph
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - Yahoo! Finance Canada
Precision BioSciences (DTIL) Secures Key Patent Allowances for P - GuruFocus
Precision BioSciences receives patent allowances for hepatitis B program - Investing.com Australia
Precision BioSciences receives patent allowances for hepatitis B program By Investing.com - Investing.com Nigeria
Precision BioSciences, Inc. Receives U.S. Patent Allowances Covering PBGENE-HBV Program - marketscreener.com
Precision BioSciences receives U.S. patent allowances covering the PBGENE-HBV program - marketscreener.com
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - TradingView
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 - BioSpace
Precision BioSciences Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Precision BioSciences (DTIL) Presents Promising Preclinical Data for DMD Therapy - GuruFocus
Precision BioSciences presents preclinical data on DMD therapy - Investing.com
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - BioSpace
Precision BioSciences to Report Q4 and Fiscal Year 2025 Results - National Today
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event - BioSpace
Precision BioSciences Says PBGENE-DMD Receives FDA Fast Track Designation - marketscreener.com
Precision BioSciences stock jumps on FDA Fast Track status By Investing.com - Investing.com Canada
FDA Grants Fast Track Status to Precision BioSciences' (DTIL) PB - GuruFocus
Forecast Cut: Is Precision BioSciences Inc gaining market shareWeekly Trade Recap & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Earnings Beat: Is Precision BioSciences Inc stock trending bullishPortfolio Update Summary & Real-Time Volume Triggers - baoquankhu1.vn
Market Outlook: Is Precision BioSciences Inc. stock a smart buy before Fed meeting2025 Investor Takeaways & Fast Gain Swing Alerts - Naître et grandir
Guidance Update: What is the long term forecast for Precision BioSciences Inc stockWeekly Trade Analysis & Verified Short-Term Trading Plans - baoquankhu1.vn
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Intellectia AI
Risk Off: Whats the outlook for Precision BioSciences Incs sectorMarket Growth Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Precision BioSciences: $7.5 Million Milestone From TG Therapeutics For Azer-Cel Clinical Progress In Multiple Sclerosis - Pulse 2.0
Forecast Cut: What is the long term forecast for Precision BioSciences Inc stockInsider Selling & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - 01net
Aug Macro: How does Precision BioSciences Inc compare to its peers2025 Price Momentum & Real-Time Volume Analysis - baoquankhu1.vn
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
Precision BioSciences Stock: Can This Tiny Gene-Editing Play Survive the Cash Crunch? - AD HOC NEWS
Stock Analysis: How does Precision BioSciences Inc compare to its peersInsider Buying & Risk Managed Investment Strategies - baoquankhu1.vn
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
DTIL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Block Trades: Is Precision BioSciences Inc a speculative investmentBear Alert & Expert Approved Trade Ideas - baoquankhu1.vn
Precision BioSciences (DTIL) Price Target Decreased by 10.55% to 33.15 - MSN
What’s the outlook for Precision BioSciences Inc.’s sector2025 Bull vs Bear & Expert Curated Trade Setups - mfd.ru
Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares - MarketBeat
Precision Biosciences Inc Azioni (DTIL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):